Business Context and Reporting Period
Heron Therapeutics, Inc. is a pre-commercial biotechnology company developing medicines for cancer and pain using its Biochronomer drug-delivery technology. This Form 10-K covers the fiscal year ended December 31, 2015; the filing also provides unaudited fourth-quarter 2015 data.
- Lead product: SUSTOL, an extended-release granisetron injection for acute and delayed chemotherapy-induced nausea and vomiting.
- Pipeline: HTX-019, an intravenous aprepitant formulation for chemotherapy-induced nausea and vomiting, and HTX-011, a long-acting bupivacaine/meloxicam formulation for post-operative pain.
- Commercial status: No products had been approved, sold or distributed as of December 31, 2015.
Financial Performance and Position
| Metric | FY 2015 | FY 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $61.2 million | $54.8 million | +11.6% |
| General and administrative expense | $35.7 million | $19.7 million | +81.2% |
| Loss from operations | $96.9 million | $74.6 million | Loss increased 30.0% |
| Net loss | $97.6 million | $76.4 million | Loss increased 27.8% |
| Net loss per share | $2.95 | $2.87 | Loss per share increased |
| Net cash used in operating activities | $78.5 million | $60.3 million | Use increased 30.3% |
| Cash, cash equivalents and short-term investments | $131.2 million | $72.7 million | +80.5% |
| Accumulated deficit | $412.8 million | $315.2 million | Increased $97.6 million |
Because the company had no revenue, gross and operating margins are not meaningful. Fourth-quarter 2015 operating expenses were $31.1 million and net loss was $31.2 million, or $0.87 per share, compared with a $20.6 million net loss, or $0.71 per share, in fourth-quarter 2014.
Financing activities provided $138.0 million in 2015, principally from a June public offering that generated $128.2 million of net proceeds and $9.5 million from stock-option exercises. Investing activities used $57.0 million, primarily for short-term investments. Cash and cash equivalents increased by $2.5 million during the year.
Debt and Liquidity
- Senior secured convertible notes had a $5.7 million principal balance and a $2.2 million carrying value at year-end, bear interest at 6%, and mature May 2, 2021.
- Noteholders may require prepayment at any time, and the notes are secured by substantially all company assets, including bank and investment accounts.
- Conversion of the notes would require issuance of approximately 7.1 million shares, representing approximately 16% dilution based on the filing’s calculation.
- Management stated that available working capital was sufficient to fund operations through 2016, including SUSTOL regulatory and launch activities and planned HTX-011 and HTX-019 development.
- Contractual obligations totaled $4.9 million, including $1.1 million of operating leases and $3.9 million of purchase obligations, principally for manufacturing and clinical development.
Material Changes Versus the Prior Comparable Period
- R&D expense increased $6.4 million, driven by higher HTX-011 and HTX-019 development costs, personnel expenses and stock-based compensation. SUSTOL costs declined $9.3 million after completion of the Phase 3 program in May 2015.
- G&A expense increased $16.0 million, primarily from SUSTOL launch preparation, commercial operations and higher stock-based compensation.
- Operating cash use increased $18.2 million to $78.5 million.
- Cash resources increased substantially because of the June 2015 equity offering, although operating losses and development spending continued to consume cash.
- Stock-based compensation increased to $14.4 million from $8.1 million.
Guidance, Outlook, Risks and Unusual Items
- The FDA did not act on the SUSTOL NDA by its January 17, 2016 PDUFA date and anticipated action in late February 2016. The company expected commercial availability in the second quarter of 2016 if approved.
- Management expected R&D and G&A expenses to increase in 2016 to support pipeline development and potential SUSTOL commercialization.
- The Phase 3 MAGIC study met its primary endpoint: delayed-phase complete response was 64.7% for SUSTOL versus 56.6% for ondansetron, an 8 percentage-point difference with p=0.014. The filing cautions that FDA approval and the scope of any label remained uncertain.
- HTX-019’s bioequivalence study was complete, and the company intended to file an NDA in the second half of 2016. HTX-011 remained in Phase 2 development.
- Key risks include another FDA complete response letter, a narrower-than-desired label, manufacturing scale-up or cGMP deficiencies, dependence on third-party manufacturers and suppliers, clinical-trial failure, competition, reimbursement pressure and the need for additional financing.
- Unusual or notable items included a $0.9 million manufacturing-equipment impairment recorded in 2014, a $40,000 unrealized loss on short-term investments in 2015, and $14.4 million of stock-based compensation in 2015.
- The company had no legal proceedings reported and no off-balance-sheet arrangements. Management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2015.
Important Facts for Investors to Verify
- FDA’s actual decision on the SUSTOL NDA, the approved indications and any post-approval requirements.
- Whether SUSTOL manufacturing scale-up, validation and third-party facility compliance support timely commercial supply.
- Cash burn and runway relative to management’s stated funding horizon, particularly if SUSTOL approval or commercialization is delayed.
- Terms, repayment rights and potential dilution associated with the secured convertible notes.
- Progress, clinical results and regulatory timelines for HTX-011 and HTX-019.
- Commercial uptake, pricing, reimbursement and competitive positioning after any SUSTOL launch.
- Potential dilution from approximately 8.4 million outstanding options, 3.6 million warrants and 7.1 million shares underlying convertible notes.